Immediate Impact

3 from Science/Nature 51 standout
Sub-graph 1 of 24

Citing Papers

Recent advances in targeted therapies in acute myeloid leukemia
2023 Standout
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
2021 Standout
1 intermediate paper

Works of Radovan Vrḫovac being referenced

AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
2022
Ruxolitinib: A New JAK1/2 Inhibitor That Offers Promising Options for Treatment of Myelofibrosis
2011

Author Peers

Author Last Decade Papers Cites
Radovan Vrḫovac 235 321 218 247 57 776
Qin Huang 391 255 215 230 61 863
L Mangoni 501 239 230 219 53 880
Milica C̆olović 451 237 254 196 84 916
E. Januszewicz 416 456 127 226 41 940
Giuseppina Massini 169 155 231 290 39 786
Stéphanie Harel 305 267 302 178 50 745
Gilles Lugassy 211 250 117 167 55 765
Rocí­o Benito 241 281 285 125 59 711
Deborah Yallop 175 417 217 179 35 757
Anand P. Jillella 473 217 305 274 53 842

All Works

Loading papers...

Rankless by CCL
2026